Hyperfine (HYPR) Capital Expenditures (QoQ) (2021 - 2026)
Hyperfine (HYPR) Capital Expenditures (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.52% |
| Dec 31, 2025 | -51.54% |
| Sep 30, 2025 | -88.39% |
| Jun 30, 2025 | 975.00% |
| Mar 31, 2025 | 85.71% |
| Dec 31, 2024 | -446.34% |
| Sep 30, 2024 | -2,242.86% |
| Jun 30, 2024 | -100.94% |
| Mar 31, 2024 | 104.97% |
| Dec 31, 2023 | 312.94% |
| Sep 30, 2023 | -2,025.00% |
| Jun 30, 2023 | -122.22% |
| Mar 31, 2023 | -82.44% |
| Dec 31, 2022 | -57.20% |
| Sep 30, 2022 | 520.18% |
| Jun 30, 2022 | -283.87% |
| Mar 31, 2022 | -89.44% |
| Dec 31, 2021 | -1.18% |
| Sep 30, 2021 | 1,663.16% |
| Jun 30, 2021 | -165.52% |